Aadi Bioscience, Inc. (AADI)

1.7800 -0.0600 (-3.26%) At close: 04:00PM EDT

Aadi Bioscience, Inc.

17383 Sunset Boulevard
Suite A250
Pacific Palisades, CA 90272
United States
424-744-8055
https://aadibio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 89

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Neil P. Desai Ph.D.	Founder, Secretary & Executive Chairman	1.12M	N/A	1965
Dr. Loretta M. Itri F.A.C.P., M.D.	Chief Medical Officer	805.85k	N/A	1950
Mr. David J. Lennon Ph.D.	President, CEO & Director	N/A	N/A	1971
Mr. Scott M. Giacobello CPA	CFO, Treasurer, Investor Relations & Corporate Communications	495.56k	N/A	1970
Mr. Stephen M. Rodin J.D.	Senior VP of Legal & General Counsel	N/A	N/A	1976
Mr. Raymond G. Steitz	Senior VP of Human Resources & Chief Human Resources Officer	N/A	N/A	1959
Mr. Bryan Ball	Chief Quality Officer & Senior VP of Manufacturing Operations	N/A	N/A	1971

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.

Corporate governance

Aadi Bioscience, Inc.’s ISS governance QualityScore as of 1 April 2024 is 8. The pillar scores are Audit: 8; Board: 7; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.